Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
Defining the clinical course of multiple sclerosis: The 2013 revisions.
Roche’s ocrelizumab first investigational medicine to show efficacy in people with primary progressive multiple sclerosis in large Phase III study
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: a multicentre retrospective study on 361 patients
BIIB033 single ascending dose study in healthy volunteer subjects
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo.
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
Risk alleles for multiple sclerosis identified by a genomewide study.
Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy.
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Multiple sclerosis and pregnancy: experience from a nationwide database in Germany.
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis.
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β-Defensins via Induction of Regulatory T Cells.
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Pages
« first
‹ previous
…
11
12
13
14
15
16
17
18
19
…
next ›
last »